Cerebral edema remains a significant cause of morbidity and mortality in patients with acute liver failure (ALF) and has been linked to elevated blood ammonia levels. l-ornithine phenylacetate (OPA) may decrease ammonia by promoting its renal excretion as phenylacetylglutamine (PAGN), decreasing the risk of cerebral edema. We evaluated the safety, tolerability, and pharmacokinetics of OPA in patients with ALF and acute liver injury (ALI), including those with renal failure. Forty-seven patients with ALI/ALF and ammonia ≥60 μM were enrolled. Patients received OPA in a dose escalation scheme from 3.3 g every 24 hours to 10 g every 24 hours; 15 patients received 20 g every 24 hours throughout the infusion for up to 120 hours. Plasma phenylacetate (PA) concentrations were uniformly below target (<75 μg/mL) in those receiving 3.3 g every 24 hours (median [interquartile range] 5.0 [5.0] μg/mL), and increased to target levels in all but one who received 20 g every 24 hours (150 [100] μg/mL). Plasma [PAGN] increased, and conversion of PA to PAGN became saturated, with increasing OPA dose. Urinary PAGN clearance and creatinine clearance were linearly related (r = 0.831, P < 0.0001). Mean ammonia concentrations based on the area under the curve decreased to a greater extent in patients who received 20 g of OPA every 24 hours compared with those who received the maximal dose of 3.3 or 6.7 g every 24 hours (P = 0.046 and 0.022, respectively). Of the reported serious adverse events (AEs), which included 11 deaths, none was attributable to study medication. The only nonserious AEs possibly related to study drug were headache and nausea/vomiting. CONCLUSION: OPA was well-tolerated in patients with ALI/ALF, and no safety signals were identified. Target [PA] was achieved at infusion rates of 20 g every 24 hours, leading to ammonia excretion in urine as PAGN in proportion to renal function. Randomized, controlled studies of high-dose OPA are needed to determine its use as an ammonia-scavenging agent in patients with ALF. (Hepatology 2018;67:1003-1013).
Cerebral edema remains a significant cause of morbidity and mortality in patients with acute liver failure (ALF) and has been linked to elevated blood ammonia levels. l-ornithine phenylacetate (OPA) may decrease ammonia by promoting its renal excretion as phenylacetylglutamine (PAGN), decreasing the risk of cerebral edema. We evaluated the safety, tolerability, and pharmacokinetics of OPA in patients with ALF and acute liver injury (ALI), including those with renal failure. Forty-seven patients with ALI/ALF and ammonia ≥60 μM were enrolled. Patients received OPA in a dose escalation scheme from 3.3 g every 24 hours to 10 g every 24 hours; 15 patients received 20 g every 24 hours throughout the infusion for up to 120 hours. Plasma phenylacetate (PA) concentrations were uniformly below target (<75 μg/mL) in those receiving 3.3 g every 24 hours (median [interquartile range] 5.0 [5.0] μg/mL), and increased to target levels in all but one who received 20 g every 24 hours (150 [100] μg/mL). Plasma [PAGN] increased, and conversion of PA to PAGN became saturated, with increasing OPA dose. Urinary PAGN clearance and creatinine clearance were linearly related (r = 0.831, P < 0.0001). Mean ammonia concentrations based on the area under the curve decreased to a greater extent in patients who received 20 g of OPA every 24 hours compared with those who received the maximal dose of 3.3 or 6.7 g every 24 hours (P = 0.046 and 0.022, respectively). Of the reported serious adverse events (AEs), which included 11 deaths, none was attributable to study medication. The only nonserious AEs possibly related to study drug were headache and nausea/vomiting. CONCLUSION: OPA was well-tolerated in patients with ALI/ALF, and no safety signals were identified. Target [PA] was achieved at infusion rates of 20 g every 24 hours, leading to ammonia excretion in urine as PAGN in proportion to renal function. Randomized, controlled studies of high-dose OPA are needed to determine its use as an ammonia-scavenging agent in patients with ALF. (Hepatology 2018;67:1003-1013).
Authors: Marwan Ghabril; Igor A Zupanets; John Vierling; Parvez Mantry; Don Rockey; David Wolf; Robert O'Shea; Klara Dickinson; Heather Gillaspy; Catherine Norris; Dion F Coakley; Masoud Mokhtarani; Bruce F Scharschmidt Journal: Clin Pharmacol Drug Dev Date: 2013-03-16
Authors: Gregory M Enns; Susan A Berry; Gerard T Berry; William J Rhead; Saul W Brusilow; Ada Hamosh Journal: N Engl J Med Date: 2007-05-31 Impact factor: 91.245
Authors: Adrian Reuben; Holly Tillman; Robert J Fontana; Timothy Davern; Brendan McGuire; R Todd Stravitz; Valerie Durkalski; Anne M Larson; Iris Liou; Oren Fix; Michael Schilsky; Timothy McCashland; J Eileen Hay; Natalie Murray; Obaid S Shaikh; Daniel Ganger; Atif Zaman; Steven B Han; Raymond T Chung; Alastair Smith; Robert Brown; Jeffrey Crippin; M Edwyn Harrison; David Koch; Santiago Munoz; K Rajender Reddy; Lorenzo Rossaro; Raj Satyanarayana; Tarek Hassanein; A James Hanje; Jody Olson; Ram Subramanian; Constantine Karvellas; Bilal Hameed; Averell H Sherker; Patricia Robuck; William M Lee Journal: Ann Intern Med Date: 2016-04-05 Impact factor: 25.391
Authors: Lars Marius Ytrebø; Rune Gangsøy Kristiansen; Hanne Maehre; Ole Martin Fuskevåg; Trine Kalstad; Arthur Revhaug; María Jover Cobos; Rajiv Jalan; Christopher F Rose Journal: Hepatology Date: 2009-07 Impact factor: 17.425
Authors: Meritxell Ventura-Cots; Mar Concepción; José Antonio Arranz; Macarena Simón-Talero; Maria Torrens; Albert Blanco-Grau; Inma Fuentes; Pilar Suñé; Edilmar Alvarado-Tapias; Cristina Gely; Eva Roman; Beatriz Mínguez; German Soriano; Joan Genescà; Juan Córdoba Journal: Therap Adv Gastroenterol Date: 2016-07-26 Impact factor: 4.409
Authors: William R Treem; Melissa Palmer; Isabelle Lonjon-Domanec; Daniel Seekins; Lara Dimick-Santos; Mark I Avigan; John F Marcinak; Ajit Dash; Arie Regev; Eric Maller; Meenal Patwardhan; James H Lewis; Don C Rockey; Adrian M Di Bisceglie; James W Freston; Raul J Andrade; Naga Chalasani Journal: Drug Saf Date: 2020-11-03 Impact factor: 5.606